- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Mabpharm Files for Infliximab Biosimilar in China; Sorrento to Seek US Biobetter Version
Sorrento Therapeutics said this week it plans a 2020 Biologics License Application in the United States for a “biobetter” of infliximab.
Sorrento Therapeutics said this week that its partner Mabpharm has filed a New Drug Application for its proposed infliximab biosimilar in China, and that it also plans a 2020 Biologics License Application (BLA) in the United States for a “biobetter” of infliximab.
Biobetters are an emerging class of follow-on biologics that could compete with biosimilars for market share. While the term “biosimilar” is applied to a drug that has been demonstrated to be highly similar to its reference, with no clinically meaningful differences from the originator product, the term “biobetter” refers to a therapy that has resulted from intentionally altering a biologic product in order to improve its clinical effects, require less frequent administration, or enhance tolerability.
Originator infliximab is sold as Remicade by Janssen.
Sorrento, through a global licensing agreement with Mabpharm, owns the global rights to Mabpharm’s infliximab biobetter antibody outside of China. Sorrento said it is planning to file all the required document for a BLA by the end of 2020.
In response to a query from The Center for Biosimilars®, a Sorrento company spokeswoman said the biobetter’s route of administration will be by infusion, but “the biobetter is expected to have some clinical differentiation (safety/efficacy).”
Mabpharm recently submitted a New Drug Application with China’s National Medical Products Administration for a biobetter anti—tumor necrosis factor-alpha chimeric monoclonal antibody based on infliximab, using a system of Chinese hamster ovary cells; the company said that results in a “potentially better safety profile and lower immunogenicity.”
Thus far, the only biobetter option to be approved in any regulatory territory is Celltrion Healthcare’s Remsima SC, a subcutaneously administered formulation of its biosimilar infliximab, CT-P13, for the treatment of rheumatoid arthritis; it was approved by the European Commission last year.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
FDA Approves Celltrion's Avtozma as Third Tocilizumab Biosimilar
January 31st 2025The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions. It is the third biosimilar to reference Actemra (tocilizumab) to be approved for US patients.
